Clinical trials: Vascular Endothelial Growth Factor
Advanced Cancer, Metastatic Cancer
Phase I Trial of Tanibirumab in Advanced or Metastatic Cancer
The primary objective of this study is to assess the safety, tolerability, and maximum tolerated dose (MTD) of Tanibirumab in patients with advanced or metastatic cancer who are refractory or for whom there are no standard…
- Trial name
- NCT01660360
- Testing
- Tanibirumab
- Where
- South Korea
- Volunteers
- 26 people
- Sponsor
- PharmAbcine
Diabetic Kidney Disease (DKD)
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
This phase 2a, double-blind, randomized, placebo-controlled study will assess the efficacy, safety, tolerability, and pharmacokinetics (PK), of repeat doses of CSL346 in subjects with diabetic kidney disease (DKD) and albuminuria…
- Trial name
- NCT04419467
- Testing
- CSL346
- Where
- 37 sites in United States, Australia and 4 more
- Volunteers
- 114 people
- Sponsor
- CSL Behring
Age-Related Macular Degeneration
Seven-year Outcomes Following Intensive Anti-VEGF Therapy in Wet AMD
The aim of this study was to assess long-term benefits of intensive aflibercept and ranibizumab anti-VEGF therapy in patients with exudative AMD.
- Trial name
- NCT05678517
- Testing
- Anti-VEGF
- Where
- 2 sites in Hungary
- Volunteers
- 47 people
- Sponsor
- Semmelweis University
Diabetic Macular Edema, Cataract
Cataract DME - Peri vs. Intraop
Goals of the study are to evaluate how peri-operative versus intra-operative anti-VEGF intravitreous injections affect visual acuity (BCVA) in patients with persistent diabetic macular edema who are undergoing cataract surgery…
- Trial name
- NCT03920878
- Testing
- Aflibercept injected Pre- and Post-operatively, Aflibercept injected intraoperatively
- Where
- 2 sites in United States
- Sponsor
- Emory University
Periodontitis, Periodontitis (Stage 3)
Evaluation of Albumin Platelet-Rich Fibrin Following SRP in Patients With Periodontitis
The study aims to investigate whether application of albumin platelet-rich fibrin (Alb-PRF) into the gum pockets after scaling and root planing (SRP) can improve healing in patients with Stage III Grade B periodontitis.
- Trial name
- NCT07363135
- Testing
- Albumin platelet-rich fibrin, Sterile saline (0.9%)
- Where
- Turkey (Türkiye)
- Volunteers
- 23 people
- Sponsor
- Saglik Bilimleri Universitesi
Macular Polypoidal Choroidal Vasculopathy (PCV)
Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy
This study is a 60-week, two-arm, randomized, open-label, active-controlled, multi-center study in patients with Polypoidal choroidal vasculopathy (PCV) who have not previously received anti-Vascular endothelial growth factor…
- Trial name
- PROUD (NCT05666804)
- Testing
- Brolucizumab 6mg
- Where
- 15 sites in South Korea
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
VEGF Early Imaging for Breast Cancer
Breast cancer is the most common cause of cancer death among women. Yearly around 12,500 Dutch women are diagnosed with breast cancer and 3,500 die of this disease.
- Trial name
- NCT00991978
- Testing
- 89Zr-bevacizumab PET
- Where
- Netherlands
- Volunteers
- 23 people
- Sponsor
- University Medical Center Groningen
Non-Small Cell Lung Cancer, Chronic Obstructive Pulmonary Disease
Detection of Circulating Endothelial Progenitors Cells (EPCs) in Non-small Cell Lung Cancer (NSCLC)
Bone-marrow-derived progenitor cells (EPCS) play an important role in neovascularization and tumor growth. In lung cancer, angiogenesis is an important event in mechanisms of tumor proliferation and metastasis.
- Trial name
- CBNPC:PCE (NCT00826683)
- Testing
- Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures
- Where
- France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Diabetic Macular Edema
Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents
Diabetic retinopathy (DR) is considered the main etiology of blindness among working-age adults, and Diabetic macular edema (DME) is the main reason for vision loss related to DR .
- Trial name
- NCT06205979
- Testing
- Ranibizumab Injection [Lucentis], Aflibercept Injection [Eylea]
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Insulin-like Growth Factor I, Insulin-like Growth Factor II
Neurotrophic Factors in Cerebrospinal Fluid in Diabetic Patients With Polyneuropathy
Background: The pathogenetic factors underlying development of diabetic polyneuropathy (DP) remain unclear. Reduced neurotrophic stimulation has been proposed as a possible mechanism.
- Conditions
- Insulin-like Growth Factor I, Insulin-like Growth Factor II, Diabetes Complications, Polyneuropathies
- Trial name
- NCT01718015
- Where
- Denmark
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Acute Ischemic Stroke
Vascular Endothelial Growth Factor and Endostatin in Angiogenesis After Acute Ischemic Stroke
Vascular endothelial growth factor (VEGF) and Endostatin (ES) participate angiogenesis after cerebral ischemia. Circulating endothelial progenitor cells (EPCs) also play a crucial role in neovascularization and tissue repair…
- Trial name
- NCT02157896
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai 6th People's Hospital
Cancer, Colon Cancer
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
This is a phase 3, randomized, double-blind, placebo-controlled multi-center study evaluating the efficacy of pegfilgrastim to reduce the incidence of febrile neutropenia (FN) in patients with newly diagnosed, locally-advanced or…
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Fever
- Trial name
- NCT00911170
- Testing
- Pegfilgrastim, Bevacizumab, Standard Chemotherapy
- Where
- 154 sites in United States, Australia and 15 more
- Volunteers
- 847 people
- Sponsor
- Amgen
Ovarian Neoplasms, Fallopian Tube Neoplasms
Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Background: Vandetanib is a drug that attacks a group of proteins on the surface of many cells, especially blood vessel cells and tumor cells. Tumors require the development of new blood vessels in order to grow and spread.
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT00445549
- Testing
- Vandetanib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Periodontal Diseases
Thiol/Disulphide Homeostasis and Vascular Endothelial Growth Factor Levels in Diabetic Children
The aim of this study to evaluate the vascular endothelial growth factor level and thiol/disulphide homeostasis in saliva of diabetic children with gingivitis.
- Trial name
- NCT04470635
- Testing
- ELISA
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Aydin Adnan Menderes University
Age-Related Macular Degeneration
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related…
- Trial name
- NCT05984927
- Testing
- NG101 AAV gene therapy
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Elisigen, Inc.
Endometrial Carcinoma
Trisenox® in Women With Metastatic Endometrial Cancer
The primary purpose of this study is to see whether women who have already received chemotherapy for their endometrial cancer, or who have disease that has spread outside of the uterus, will respond to the drug arsenic trioxide…
- Trial name
- NRR (NCT01184053)
- Testing
- Arsenic trioxide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Telangiectasia
Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation
This study will examine whether the drug ranibizumab is an effective treatment for macular telangiectasia, a condition in which existing blood vessels near the macula (the back part of the eye responsible for sharp central…
- Trial name
- NCT00457145
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Macular Edema
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
Although multiple studies have suggested that treatment with ranibizumab is safe and efficacious and superior to focal/grid laser alone for patients with center-involved diabetic macular edema (DME), there may be barriers in…
- Trial name
- Protocol T (NCT01627249)
- Testing
- 2.0 mg intravitreal aflibercept, 1.25 mg intravitreal bevacizumab, 0.3 mg intravitreal ranibizumab
- Where
- 90 sites in United States
- Volunteers
- 660 people
- Sponsor
- Jaeb Center for Health Research
Osteosarcoma, Malignant Fibrous Histiocytoma (MFH) of Bone
A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
This study adopts a novel strategy for first-line treatment of osteosarcoma by combining chemotherapy with anti-angiogenic therapy using bevacizumab (Avastin®), a humanized monoclonal antibody against vascular endothelial growth…
- Trial name
- NCT00667342
- Testing
- Bevacizumab, Cisplatin, Doxorubicin
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- St. Jude Children's Research Hospital
Pancreatic Cancer, Pancreas Neoplasms
Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
Pancreatic cancer is the fourth leading cause of cancer death in the United States, and no combination therapy is far superior to gemcitabine alone.
- Trial name
- NCT00683085
- Testing
- HLA-A*02:01-restricted VEGFR1-derived peptide vaccination
- Where
- Japan
- Volunteers
- 2 people
- Sponsor
- Tokyo University